Delivery Order 36F79720D0099-36C24524N0893
Award Date
9/6/24
Potential Completion Date
9/11/24
Potential Value
$13K
Federal Agency
Veterans Integrated Service Network 5
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Pittsburgh, PA 15275, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was made by the U.S. Department of Veterans Affairs (VA) to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer and supplier. The award, valued at $12,559.90, is for the delivery of the drug Jynarque (tolvaptan) in 90mg/30mg dosage to VA medical facilities and integrated service networks. Jynarque is used to treat autosomal dominant polycystic kidney disease and hyponatremia. The contract is a Delivery Order issued under Otsuka's existing...
This federal contract award to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer, was issued by the U.S. Department of Veterans Affairs (VA) for the delivery of the prescription drug Jynarque (tolvaptan). The contract is a delivery order valued at $12,559.90 and has a completion date of November 13, 2024. Jynarque is used to treat autosomal dominant polycystic kidney disease and hyponatremia. Otsuka America Pharmaceutical holds two Indefinite Delivery Vehicles (IDVs)...
This federal contract award was made by the Department of Veterans Affairs (VA) to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer. The $13,168.39 firm-fixed price delivery order is for the supply of JYNARQUE 90MG-30MG, a drug used to treat autosomal dominant polycystic kidney disease and hyponatremia. The contract, which has an ultimate completion date of May 2, 2025, was awarded on April 30, 2025 under the Pharmaceuticals and Drugs Federal Supply Schedule...
This federal contract award is for the drug JYNARQUE, which is used to treat autosomal dominant polycystic kidney disease and hyponatremia. The $100,645.76 firm-fixed price delivery order was awarded to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer, by the U.S. Department of Veterans Affairs (VA) under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The contract has an ultimate completion date of March 25, 2024. Otsuka holds two significant...
This federal contract award to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer, is for the delivery of the drug Jynarque (tolvaptan) to the U.S. Department of Veterans Affairs (VA). The contract, valued at $12,580.72, is a delivery order issued under two larger Indefinite Delivery Vehicles (IDVs) held by Otsuka with the VA: a $15 million Blanket Purchase Agreement (BPA) and a $396 million Federal Supply Schedule (FSS) contract, both awarded in March 2020 and set to...
This federal contract award was made by the Department of Veterans Affairs (VA) to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer and supplier. The contract is for the delivery of the medication Jynarque (tolvaptan), which is used to treat autosomal dominant polycystic kidney disease and hyponatremia. The contract is a Blanket Purchase Agreement (BPA) with a ceiling value of $113,303.91 and a period of performance from October 2020 to October 2021. It was awarded...
This federal contract award was issued by the Department of Veterans Affairs (VA) to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer and supplier. The contract, valued at $12,559.90, is a delivery order under Otsuka's existing Blanket Purchase Agreement (BPA) and Federal Supply Schedule (FSS) contract with the VA. The award is for the drug JYNARQUE 90MG/30MG, which is used to treat autosomal dominant polycystic kidney disease and hyponatremia. Otsuka has supplied...
This federal contract award is for the delivery of the pharmaceutical drug Jynarque (tolvaptan) to the U.S. Department of Veterans Affairs (VA) by Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer. The contract has an award value of $12,559.90 and a period of performance through August 6, 2024. Jynarque is used to treat autosomal dominant polycystic kidney disease and hyponatremia. The contract was issued under Otsuka's Federal Supply Schedule (FSS) contract with the...
This is a firm-fixed price delivery order contract awarded by the Department of Veterans Affairs (VA) to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer and supplier. The contract, valued at $730,030.82, is for the delivery of the drug Jynarque (tolvaptan) to VA medical facilities across the country. Jynarque is used to treat autosomal dominant polycystic kidney disease and hyponatremia. The contract is issued under the VA's Pharmaceuticals and Drugs Federal Supply...
Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer, was awarded a delivery order contract by the Department of Veterans Affairs (VA) Veterans Health Administration to provide the drug JYNARQUE for the treatment of kidney disorders. The $282,855.34 firm-fixed-price contract has a completion date of June 30, 2023 and was awarded on July 1, 2022. The contract is issued under Otsuka's existing Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB),...